Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company that discovers, develops and commercializes medicines for serious diseases, with a focus on specialty markets. Its approved products treat cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain.… From the company’s description.
In fiscal 2025, Vertex Pharmaceuticals reported revenue of $12.00B, up 8.9% from fiscal 2024, and net income of $3.95B. Its operating margin was 34.8%, and operations generated $3.63B in cash. Over the twelve months to Jun 30, 2026, revenue was $12.59B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vertex Pharmaceuticals does
In the company’s own words
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company that discovers, develops and commercializes medicines for serious diseases, with a focus on specialty markets. Its approved products treat cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. The cystic fibrosis portfolio includes ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO; CASGEVY is a gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX treats acute pain in adults. Vertex sells medicines mainly through specialty pharmacies and distributors, wholesalers, retail pharmacies, hospitals and authorized treatment centers, with governments and other payors involved in access and reimbursement. It reports as a single business segment. Its clinical pipeline spans kidney diseases, pain, type 1 diabetes and other conditions, including pivotal programs in IgA nephropathy, APOL1-mediated kidney disease, diabetic peripheral neuropathy, type 1 diabetes and primary membranous nephropathy. In 2025, Vertex acquired Alpine Immune Sciences, adding the kidney-disease candidate povetacicept. Its website is https://www.vrtx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 875320
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vertex Pharmaceuticals — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Vertex Pharmaceuticals · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Vertex Pharmaceuticals’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vertex Pharmaceuticals and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vertex Pharmaceuticals's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vertex Pharmaceuticals's last four quarterly filings that the numbers alone won't show?”